Aplin, Andrew E.

Mutant BRAF and MEK inhibitors regulate the tumor immune microenvironment via pyroptosis

Erkes, D. A., Cai, W., Sanchez, I. M., Purwin, T. J., Rogers, C., Field, C. O., Berger, A. C., Hartsough, E. J., Rodeck, U., Alnemri, E. S., et al. (2020) · Cancer Discovery

Melanoma and MAPK PathwaysCancer Immunotherapy and Biomarkers

Cited by 459

Mitochondrial H2O2 Regulates the Angiogenic Phenotype via PTEN Oxidation

Connor, K. M., Subbaram, S., Regan, K. J., Nelson, K. K., Mazurkiewicz, J. E., Bartholomew, P. J., Aplin, A. E., Tai, Y.-T., Aguirre-Ghiso, J., Flores, S. C., et al. (2005) · Journal of Biological Chemistry

Redox biology and oxidative stressAngiogenesis and VEGF in Cancer

Cited by 251

In Vitro Phosphorylation of the Cytoplasmic Domain of the Amyloid Precursor Protein by Glycogen Synthase Kinase‐3β

Aplin, A. E., Gibb, G. M., Jacobsen, J. S., Gallo, J., & Anderton, B. H. (1996) · Journal of Neurochemistry

Alzheimer's disease research and treatmentsProtein Kinase Regulation and GTPase Signaling

Cited by 201

Sestrin2 Protein Positively Regulates AKT Enzyme Signaling and Survival in Human Squamous Cell Carcinoma and Melanoma Cells

Zhao, B., Shah, P., Budanov, A. V., Qiang, L., Ming, M., Aplin, A., Sims, D. M., & He, Y.-Y. (2014) · Journal of Biological Chemistry

PI3K/AKT/mTOR signaling in cancerSkin Protection and Aging

Cited by 61

Response and Resistance to Paradox-Breaking BRAF Inhibitor in Melanomas In Vivo and Ex Vivo

Hartsough, E. J., Kugel, C. H., Vido, M. J., Berger, A. C., Purwin, T. J., Goldberg, A., Davies, M. A., Schiewer, M. J., Knudsen, K. E., Bollag, G., et al. (2018) · Molecular Cancer Therapeutics

Melanoma and MAPK PathwaysLung Cancer Treatments and Mutations

Cited by 27

PAX3 and FOXD3 Promote CXCR4 Expression in Melanoma

Kubic, J. D., Lui, J. W., Little, E. C., Ludvik, A. E., Konda, S., Salgia, R., Aplin, A. E., & Lang, D. (2015) · Journal of Biological Chemistry

Chemokine receptors and signalingMelanoma and MAPK Pathways

Cited by 25

Activation of CD8(+) T cells contributes to antitumor effects of CDK4/6 inhibitors plus MEK inhibitors

Teh, J. L. F., Erkes, D. A., Cheng, P. F., Tiago, M., Wilski, N. A., Field, C. O., Chervoneva, I., Levesque, M. P., Xu, X., Dummer, R., et al. (2020) · Cancer Immunology Research

Melanoma and MAPK PathwaysCancer Immunotherapy and Biomarkers

Cited by 22